// App-Quantinova.ai

868 : Creating a superior, site-specific anti-HER2 antibody-drug conjugate (NG-HER2 ADC) for treatment of solid tumors

Researchers

Presenter

  • Dangshe Ma

Principal Investigators

  • Bitha Narayanan

  • Kim Marquette

  • Edmund Graziani

  • Frank Loganzo

  • Manoj Charati

  • Nadira Prashad

  • Nathan Tumey

  • Jon Golas

  • Christine Hosselet

  • George Hu

  • Frank Barletta

  • Alison Betts

  • Judy Lucas

  • Chris ODonnell

  • Lioudmila Tchistiakova

  • Hans-Peter Gerber

  • Puja Sapra

Medical Centers

  • Pfizer Inc, Pearl River, CA.

  • Pfizer Inc., Cambridge, MA

  • Pfizer, Groton, CT

Locations

  • United States

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Gastric Cancer

  • Solid malignancies

  • Neutropenia

  • Non Small Cell Lung cancer

Biomarkers

  • Cluster of differentiation 8A

  • Human epidermal growth factor receptor 2

  • Apparent diffusion coefficient

Drug/Treatment

  • Trastuzumab emtansine

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Pharmacodynamics

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved